Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. ARVN
ARVN logo

ARVN News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

ARVN News

Insider Buying by Waters and Arvinas Directors

3d agoNASDAQ.COM

Arvinas, Inc. Q4 2025 Earnings Call Insights

Feb 24 2026seekingalpha

Arvinas Reports Q4 Earnings Miss with Significant Revenue Decline

Feb 24 2026seekingalpha

Arvinas Scheduled to Announce Q4 Earnings on February 24

Feb 23 2026seekingalpha

Arvinas Appoints New CEO Randy Teel Amid 11% Stock Drop

Feb 12 2026stocktwits

Arvinas Appoints New CEO and Board Chair

Feb 12 2026seekingalpha

Analysis of Rapid Growth in the PROTAC Market

Feb 10 2026Newsfilter

Arvinas Initiates ARV-393 and Glofitamab Combination Trial for DLBCL Expected in 2026

Dec 06 2025Globenewswire

ARVN Events

No data

No data

ARVN Monitor News

ARVN.O Hits 20-Day High Amid Positive Momentum

Nov 18 2025

ARVN Earnings Analysis

No Data

No Data

People Also Watch